… In head‐to‐head comparisons of angiotensin converting enzyme (ACE) inhibitors versus
angiotensin receptor blockers (ARB) for primary hypertension, moderate‐quality evidence …

… a patient with hypertension using angiotensin receptor blockers is deciding …
angiotensin receptor blockers, the dose‐related blood pressure lowering effect of this anti‐hypertensive …

… In hypertensive patients… angiotensin II receptor blocker candesartan improves tonic nitric
oxide release and reduces vasoconstriction to endogenous ET-1 in the forearm of hypertensive …

… and demonstrated no differential effects between ACE inhibitors and ARBs related to the
reduction of urinary protein or albumin excretion among patients with essential hypertension. …

… believe that β blockers should not remain first choice in the treatment of primary hypertension
and … not be used as reference drugs in future randomised controlled trials of hypertension. …

… 29 whereas the β-blocker atenolol was without effect. … hypothesis that in patients with
essential hypertension, treatment for 1 year with the AT 1 antagonist losartan would correct altered …

… -angiotensin system (RAS), specifically angiotensin II, is a key component in the pathogenesis
of hypertension… [8,9] The binding of angiotensin II to angiotensin II type 1 (AT 1 ) receptors …

… of the selective Ang II antagonist valsartan 17 in essential hypertensive patients was shown
… with this Ang II antagonist on LVH versus the β-adrenergic receptor antagonist atenolol. β-…

… The renin-angiotensin system, specifically angiotensin II, is implicated in the pathogenesis
of essential hypertension, renovascular hypertension, congestive heart failure, and renal …

… hypertension in adults in primary care.Randomised controlled trial data show that untreated
patients with essential hypertension … younger patients with essential hypertension, especially …